Equities analysts expect that Heron Therapeutics, Inc. (NASDAQ:HRTX) will announce sales of $4.53 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Heron Therapeutics’ earnings, with the highest sales estimate coming in at $4.70 million and the lowest estimate coming in at $4.36 million. The firm is scheduled to announce its next quarterly earnings report on Monday, August 14th.
On average, analysts expect that Heron Therapeutics will report full year sales of $4.53 million for the current financial year, with estimates ranging from $21.02 million to $22.90 million. For the next fiscal year, analysts expect that the firm will report sales of $83.90 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.06. The business had revenue of $3.63 million for the quarter, compared to analysts’ expectations of $1.96 million.
HRTX has been the subject of several analyst reports. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a report on Friday, May 12th. Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 9th. Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, August 3rd. Aegis restated a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a report on Tuesday, July 18th. Finally, Jefferies Group LLC restated a “buy” rating and set a $26.00 price target on shares of Heron Therapeutics in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $31.00.
Several large investors have recently added to or reduced their stakes in HRTX. Airain ltd acquired a new stake in Heron Therapeutics during the second quarter valued at approximately $442,000. Royce & Associates LP acquired a new stake in Heron Therapeutics during the second quarter valued at approximately $796,000. Legal & General Group Plc boosted its stake in Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 2,383 shares during the period. Bank of New York Mellon Corp boosted its stake in Heron Therapeutics by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock valued at $2,837,000 after buying an additional 14,086 shares during the period. Finally, State of Wisconsin Investment Board acquired a new stake in Heron Therapeutics during the second quarter valued at approximately $457,000.
Heron Therapeutics (NASDAQ HRTX) opened at 15.85 on Wednesday. The firm’s 50-day moving average is $15.24 and its 200-day moving average is $14.47. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $24.00.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.